Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v11-FR | Version v5-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2021-03-04 | 2020-09-22 |
| Drug Identification Number | 02354632 | 02354632 |
| Brand name | TEVA-ROSUVASTATIN | TEVA-ROSUVASTATIN |
| Common or Proper name | ROSUVASTATIN 40MG TAB | ROSUVASTATIN 40MG TAB |
| Company Name | TEVA CANADA LIMITED | TEVA CANADA LIMITED |
| Ingredients | ROSUVASTATIN | ROSUVASTATIN |
| Strength(s) | 40MG | 40MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | p pack 30's | p pack 30's |
| ATC code | C10AA | C10AA |
| ATC description | LIPID MODIFYING AGENTS, PLAIN | LIPID MODIFYING AGENTS, PLAIN |
| Reason for shortage | Shortage of an inactive ingredient or component. | Shortage of an inactive ingredient or component. |
| Anticipated start date | ||
| Actual start date | 2020-07-14 | 2020-07-14 |
| Estimated end date | 2021-04-30 | 2021-01-31 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Allocating 100% of Teva market for duration of risk period. | Allocating 100% of Teva market until Sep 2020 |
| Health Canada comments |